Showing 1 - 10 of 1,299
; Innovation ; Pharmaceuticals ; Health care expenditure ; Cointegration …
Persistent link: https://www.econbiz.de/10003900852
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...
Persistent link: https://www.econbiz.de/10003900791
Persistent link: https://www.econbiz.de/10012632073
There have been many studies of the volume-outcome relationship. In all of these, the unit of analysis is the hospital or physician. However, this level of analysis is mostly limited to the use of in-hospital mortality rates and is particularly sensitive to selective referral. Moreover, the...
Persistent link: https://www.econbiz.de/10008695986
The paper studies the incentive for providers to invest in new health care technologies under alternative payment systems, when the patients' benefits are uncertain. If the reimbursement by the purchaser includes both a variable (per patient) and a lump-sum component, efficiency can be ensured...
Persistent link: https://www.econbiz.de/10008746927
Persistent link: https://www.econbiz.de/10012588330
Persistent link: https://www.econbiz.de/10014246459
Persistent link: https://www.econbiz.de/10013477485
This study investigates the effectiveness of dynamic norm nudges in promoting second-dose HPV vaccinations among trendsetters-parents who initiated the firstdose HPV vaccine for their daughters between 2017-2020. Utilizing administrative data from Bogota's Secretariat of Health in a field...
Persistent link: https://www.econbiz.de/10014540586
Persistent link: https://www.econbiz.de/10013407493